WSJ: Now the outsider [from Ralph Nader's Health Research Group] is going inside, mirroring a larger shift in the Washington pendulum toward tougher company regulation. To the consternation of the drug industry, Dr. Wolfe has been appointed to a four-year term on the FDA's Drug Safety and Risk Management Committee, which plays a key role in telling the agency which drugs are safe.What's more, he has the ear of several health leaders and members of Congress expected to influence FDA policy in the Obama administration. Joshua Sharfstein, a former aide to liberal Rep. Henry Waxman, who is leading the Obama transition team assessing the FDA, worked for Dr. Wolfe years ago.
5 comments:
Thank you. My colleagues in Regulatory and Compliance don't consider this to be as bad news as our clients do!
Yea, right. This weenie hasn't come across a drug he didn't want to ban, except maybe aspirin, yet.
Actually, he probably would ban aspirin. It causes more fatal gastroinestinal bleeding than any other drug.
Is Sydney Wolf responsible for getting Darvocet pulled off the market? That move has all the earmarks of his work.
Dr. Davis, Thanks for commenting. From what I have read, admittedly just a little, in December 2010 Xanodyne Pharmaceuticals agreed to stop selling Darvocet in the U.S. after the evidence of cardiac injuries.
Post a Comment